title: Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience.
abstract: AK-2123, is a nitrotriazole with a potential to sensitize hypoxic tissue to radiation. Cancer of cervix in advanced stages are predominantly treated with radiation. These are the tumours which harbour a large hypoxic core. This is an Indian experience of the multicentric trial. Patients were randomized to control and AK-2123 arm. 49 patients were randomized to each group. Patients received external radiation with telecobalt to a dose of 50 Gy in five weeks. Those in the study arm received 600 mg/m2, on alternate days. The patients were further treated with intracavitory radiation a dose of 20 Gy. The total dose of 70 Gy was achieved. Patients in the study arm had a complete response of 71.43% (35 of 49) while only 21 of 49 (42.86%) responded in the control group. The overall survival at two years was 72.2% for the study group and 32.43% for control. Neuropathy, a drug related toxicity was transient except, in one patient, which has persisted. AK-2123, has shown significant radiation sensitizing potential.
authors.affiliation: Division of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai-400 056, India.
authors.forename: Nagraj G
authors.initials: NG
authors.lastname: Huilgol
authors.forename: Werner
authors.initials: W
authors.lastname: Dobrowsky
authors.forename: Hideo
authors.initials: H
authors.lastname: Tatsuzaki
authors.forename: Neela A
authors.initials: NA
authors.lastname: Chatterjee
authors.forename: V T
authors.initials: VT
authors.lastname: Kagiya
authors.forename: Kaushik
authors.initials: K
authors.lastname: Das
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D015996:Survival Rate; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*
chemical_list: D011838:Radiation-Sensitizing Agents; D014230:Triazoles; C072690:AK 2123